AU2001248281A1 - Pharmaceutical composition of modified pna molecules - Google Patents
Pharmaceutical composition of modified pna moleculesInfo
- Publication number
- AU2001248281A1 AU2001248281A1 AU2001248281A AU4828101A AU2001248281A1 AU 2001248281 A1 AU2001248281 A1 AU 2001248281A1 AU 2001248281 A AU2001248281 A AU 2001248281A AU 4828101 A AU4828101 A AU 4828101A AU 2001248281 A1 AU2001248281 A1 AU 2001248281A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- pna molecules
- modified pna
- modified
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000587 | 2000-04-06 | ||
DKPA200000587 | 2000-04-06 | ||
PCT/DK2001/000238 WO2001076636A2 (en) | 2000-04-06 | 2001-04-06 | Pharmaceutical composition of modified pna molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001248281A1 true AU2001248281A1 (en) | 2001-10-23 |
Family
ID=8159411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001248281A Abandoned AU2001248281A1 (en) | 2000-04-06 | 2001-04-06 | Pharmaceutical composition of modified pna molecules |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040072743A1 (en) |
EP (1) | EP1296718A1 (en) |
AU (1) | AU2001248281A1 (en) |
WO (1) | WO2001076636A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0026924D0 (en) | 2000-11-03 | 2000-12-20 | Univ Cambridge Tech | Antibacterial agents |
US20040063906A1 (en) * | 2000-11-24 | 2004-04-01 | Nielsen Peter E. | Pna analogues |
AU2002216946A1 (en) * | 2001-01-05 | 2002-07-16 | Pantheco A/S | Modified pna molecules |
US20050260131A1 (en) * | 2004-05-20 | 2005-11-24 | General Electric Company | Pharmaceuticals for enhanced delivery to disease targets |
WO2006085973A2 (en) | 2004-07-02 | 2006-08-17 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
CA2614191C (en) * | 2005-07-13 | 2015-06-30 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
FR2953555B1 (en) * | 2009-12-07 | 2012-04-06 | Snecma | ASSEMBLY OF A RETAINING RING AND A HOLDING FLANGE FOR SAID JOB |
KR20200133284A (en) | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
CN101891804B (en) * | 2010-06-21 | 2012-12-26 | 中国人民解放军第四军医大学 | Antisense peptide nucleic acid of cell penetrating peptide-mediated antibacterial RNA polymerase sigma 70 factor gene rpoD |
WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
US9278987B2 (en) | 2011-11-18 | 2016-03-08 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
EP2828395B1 (en) | 2012-03-20 | 2018-10-24 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
WO2014144442A2 (en) * | 2013-03-15 | 2014-09-18 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834430A (en) * | 1995-05-31 | 1998-11-10 | Biosynth S.R.L. | Potentiation of antibiotics |
GB2341390B (en) * | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
WO2001027261A2 (en) * | 1998-11-11 | 2001-04-19 | Pantheco A/S | Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
-
2001
- 2001-04-06 US US10/240,641 patent/US20040072743A1/en not_active Abandoned
- 2001-04-06 AU AU2001248281A patent/AU2001248281A1/en not_active Abandoned
- 2001-04-06 EP EP01921241A patent/EP1296718A1/en not_active Withdrawn
- 2001-04-06 WO PCT/DK2001/000238 patent/WO2001076636A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001076636A3 (en) | 2002-02-28 |
EP1296718A1 (en) | 2003-04-02 |
WO2001076636A2 (en) | 2001-10-18 |
US20040072743A1 (en) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002363236A1 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
AU2001250420A1 (en) | Pharmaceutical compositions | |
AU2001274307A1 (en) | Pharmaceutical compositions | |
AU2001233081A1 (en) | Composition for treatment of stress | |
AU2002302147A1 (en) | Pharmaceutical composition | |
AU2001248281A1 (en) | Pharmaceutical composition of modified pna molecules | |
AU2002258221A1 (en) | Medicinal composition | |
AU2001290239A1 (en) | Medicinal composition | |
AU2001267428A1 (en) | Direct detection of individual molecules | |
AU5460800A (en) | Pharmaceutical transdermal compositions | |
AU2001273919A1 (en) | Pharmaceutical compositions | |
AU4085201A (en) | Pharmaceutical composition | |
AU2002244865A1 (en) | Pharmaceutical composition of ibuprofen | |
AU2002246659A1 (en) | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds | |
AU2002246658A1 (en) | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds | |
AU4914400A (en) | Novel pharmaceutical composition | |
AU2002216946A1 (en) | Modified pna molecules | |
AU2001278705A1 (en) | Pharmaceutical composition | |
AU3586401A (en) | Pharmaceutical composition | |
AUPQ884500A0 (en) | Novel therapeutic molecules and uses therefor - III | |
AU2001260083A1 (en) | New pharmaceutical composition and the process for its preparation | |
AUPR529701A0 (en) | Pharmaceutical composition | |
AU2001285737A1 (en) | Pharmaceutical compositions | |
AU2001276556A1 (en) | Novel pharmaceutical use of quinnoline derivatives | |
AUPQ678400A0 (en) | Pharmaceutical composition |